BioArctic, Mesenkia partner to develop BrainTransporter-enabled antibody for glioblastoma

• BioArctic entered an oncology research collaboration with Mesenkia to develop an antibody-based treatment concept for glioblastoma.
• Work combines BrainTransporter technology with a Mesenkia KITAIbodies antibody targeting HVEM on glioblastoma cells, including stem-like cells.
• BioArctic will create a new drug candidate using the combined approach.
• Partners plan joint preclinical studies to test the concept, then decide on further development based on results.
• Collaboration expands BrainTransporter R&D beyond neurodegeneration into oncology, targeting brain delivery as a key constraint in glioblastoma therapy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioArctic AB published the original content used to generate this news brief via Cision (Ref. ID: 202608190515BITN____UKPR__SV_20260819-BIT-9480-0) on August 19, 2026, and is solely responsible for the information contained therein.